Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunological mediators.

N V Christou1, J Tellado-Rodriguez

  • 1Department of Surgery, McGill University, Montreal, Quebec.

Progress in Clinical and Biological Research
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, London, Ont., Sept. 19 to 22, 2002.

Canadian journal of surgery. Journal canadien de chirurgie·2023
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.

Canadian journal of surgery. Journal canadien de chirurgie·2023
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Society, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, London, Ont. Sept. 15-18, 2011.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Physical activity and sitting time in bariatric surgery patients 1-16 years post-surgery.

Clinical obesity·2015
Same author

The role of excess subcutaneous fat in pain and sensory sensitivity in obesity.

European journal of pain (London, England)·2013
Same author

Hemorrhagic shock resuscitation with a low molecular weight starch reduces neutrophil-endothelial interactions and vessel leakage in vivo.

Surgical infections·2003

Neutralizing cachectin (tumor necrosis factor-alpha) with antibodies may treat sepsis. This approach could offer early intervention for septic shock by targeting a key inflammatory mediator.

Area of Science:

  • Immunology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Cachectin (tumor necrosis factor-alpha) is a central mediator of inflammation.
  • Cachectin plays a critical role in the pathogenesis of sepsis and septic shock.
  • Current therapeutic strategies for sepsis often target downstream inflammatory effects.

Purpose of the Study:

  • To investigate the potential of cachectin-neutralizing antibodies as a therapeutic intervention for sepsis and septic shock.
  • To explore the feasibility of targeting cachectin in the early stages of septic shock.
  • To highlight the importance of quantifying cellular activation and cytokine production for monitoring and treatment.

Main Methods:

  • Administration of polyclonal antiserum against mouse cachectin in a mouse model.

Related Experiment Videos

  • Evaluation of resistance to the lethal effects of lipopolysaccharide (LPS).
  • Conceptual proposal for the use of monoclonal antibodies against human cachectin.

    • Main Results:

    • Mice treated with anti-cachectin antiserum demonstrated resistance to lethal doses of LPS.
    • This suggests that neutralizing cachectin can mitigate the severe consequences of endotoxemia.
    • The findings support the potential efficacy of cachectin-targeted therapies.

    Conclusions:

    • Neutralizing monoclonal antibodies against human cachectin may be a viable therapeutic option for sepsis and septic shock.
    • Early intervention targeting cachectin could be particularly effective.
    • In vivo monitoring of cellular activation and cytokine production is crucial for developing rational therapeutic approaches.